Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMPROVE trial of dapagliflozin for albuminuria reduction in type 2 diabetes
NL-OMON23733Not yet recruiting
- Sponsor
- University Medical Center Groningen
- Start
- Jun 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, double-blind trial of dapagliflozin in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by University Medical Center Groningen. Primary endpoint: Reduction in 24-hour urinary albumin excretion. Planned start Jun 2014; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON23733.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23733.